PCRX

Pacira BioSciences, Inc.

PCRX.US pacira.com
25.22
-0.14 (-0.55%)
USD · NASDAQ
52-week range
18.80
27.66
Trading at 72% of the 52-week range
Market Cap
1.01B
P/E Ratio
72.46
Forward P/E
6.44
Book Value
16.87
Div. Yield
N/A
% Institutions
113.26%
% Insiders
1.74%

1 Year

-6.2%

3 Year

-24.9%

10 Year

-40.1%
Description

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Brisbane, California.

Company Information

Company Name
Pacira BioSciences, Inc.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Exchange
NASDAQ
ISIN: US6951271005
CIK: 0001396814
CUSIP: 695127100
Currency: USD
Full Time Employees: 825
Phone: 650 242 8052
Website: pacira.com
Fiscal Year End: December
IPO Date: Feb 03, 2011
Description:

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Brisbane, California.

Address:

2000 Sierra Point Parkway, Brisbane, CA, United States, 94005

People

Directors & Officers

Name Title Year Born
Mr. Frank D. Lee CEO & Director 1968
Mr. Shawn M. Cross Chief Financial Officer 1968
Ms. Kristen Williams Esq., J.D. Chief Administrative Officer & Secretary 1974
Dr. Jonathan Slonin M.D. Chief Medical Officer 1975
Mr. Brendan P. Teehan Chief Commercial Officer 1969
Ms. Lauren Bullaro Riker Principal Accounting Officer & Senior VP of Finance 1979
Ms. Susan Mesco Head of Investor Relations NA
Mr. Anthony Molloy III, Esq. Chief Legal & Compliance Officer 1974
Mr. Christopher C. Young Chief Manufacturing Officer 1972
Ms. Krys Corbett Esq. Chief Business Officer NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Apr 23, 2026 Shawn Cross N/A Sale 12.94K $25.16 $325.60K
Apr 22, 2026 Shawn Cross N/A Sale 1.50K $25.01 $37.52K
Apr 21, 2026 Shawn Cross N/A Sale 2.85K $25.01 $71.15K
Apr 20, 2026 Shawn Cross N/A Sale 7.71K $25.14 $193.93K
Mar 17, 2026 Jonathan Slonin N/A Sale 3.26K $22.82 $74.42K
Feb 02, 2026 Lauren Riker N/A Sale 4.00K $20.81 $83.24K
Jan 05, 2026 Lauren Riker N/A Sale 1.42K $24.24 $34.32K
Dec 10, 2025 Shawn Cross N/A Sale 9.10K $25.14 $228.87K
Dec 09, 2025 Shawn Cross N/A Sale 15.90K $25.03 $397.88K
Nov 17, 2025 Jonathan Slonin N/A Sale 3.96K $24.09 $95.40K
Nov 17, 2025 Jonathan Slonin N/A Sale 3.96K $24.09 $95.40K
Aug 07, 2025 Marcelo Bigal N/A Sale 4.91K $23.67 $116.27K
Jun 04, 2025 Lauren Riker N/A Sale 5.58K $26.21 $146.20K

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
BlackRock Inc 6.74M Mar 31, 2026 16.90% $0.00 -4.66%
Doma Perpetual Capital Management LLC 2.78M Jun 30, 2026 6.97% $16.36 0.00%
Vanguard Portfolio Management, LLC 2.50M Mar 31, 2026 6.27% $0.00 0.00%
Dimensional Fund Advisors, Inc. 2.10M Jun 30, 2026 5.28% $0.01 2.07%
D. E. Shaw & Co LP 1.95M Jun 30, 2026 4.89% $0.02 -1.63%
State Street Corp 1.92M Mar 31, 2026 4.82% $0.00 1.92%
Renaissance Technologies Corp 1.83M Mar 31, 2026 4.58% $0.06 -3.11%
Vanguard Capital Management, LLC 1.78M Mar 31, 2026 4.48% $0.00 0.00%
The Goldman Sachs Group Inc 1.57M Mar 31, 2026 3.94% $0.00 20.73%
Morgan Stanley - Brokerage Accounts 1.39M Mar 31, 2026 3.49% $0.00 16.77%
Geode Capital Management, LLC 1.14M Mar 31, 2026 2.87% $0.00 -2.20%
American Century Companies Inc 1.02M Jun 30, 2026 2.55% $0.01 21.55%
Impax Asset Management Group PLC 750.03K Jun 30, 2026 1.88% $0.12 0.00%
Charles Schwab Investment Management Inc 732.04K Mar 31, 2026 1.84% $0.00 8.23%
Two Sigma Investments LLC 724.60K Jun 30, 2026 1.82% $0.01 37.53%
Gagnon Securities LLC 608.62K Jun 30, 2026 1.53% $2.98 -1.44%
LSV Asset Management 608.38K Jun 30, 2026 1.53% $0.03 17.65%
Wellington Management Company LLP 563.46K Jun 30, 2026 1.41% $0.00 17.78%
UBS Group AG 562.04K Mar 31, 2026 1.41% $0.00 0.61%
Northern Trust Corp 519.41K Mar 31, 2026 1.30% $0.00 -1.72%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 iShares Core S&P Small-Cap ETF 2.39M 6.01% ▼ 0.37% Aug 31, 2026
2 Vanguard MStar Total Stk Mkt Idx Invest 1.20M 3.01% ▲ 0.00% Jul 31, 2026
3 iShares Russell 2000 ETF 1.02M 2.55% ▼ 0.57% Aug 31, 2026
4 Vanguard Small Cap Index 858.33K 2.15% ▲ 0.42% Jul 31, 2026
5 Impax US Small Cap Strategy Composite 750.03K 1.88% ▲ 0.00% Jun 30, 2026
6 Impax Small Cap Institutional 750.03K 1.88% ▲ 0.00% Jul 31, 2026
7 Avantis US Small Cap Value ETF 681.16K 1.71% ▲ 0.86% Aug 31, 2026
8 DFA US Small Cap Value I 570.18K 1.43% ▲ 0.00% Jul 31, 2026
9 Vanguard MStar Small Cap Value Index 545.54K 1.37% ▲ 0.47% Jul 31, 2026
10 Vanguard Institutional Extnd Mkt Idx Tr 454.48K 1.14% ▲ 0.19% Jul 31, 2026

Financial Highlights

Market Cap: $1.01B
EBITDA: $123.97M
P/E Ratio: $72.46
PEG Ratio: $11.21
Book Value: $16.87
Earnings/Share: $0.35
Profit Margin: 1.96%
Operating Margin: 6.17%
ROA (TTM): 1.48%
ROE (TTM): 2.05%
Revenue (TTM): $746.16M
Revenue/Share (TTM): $17.93
Earnings Growth (YOY): -30.00%
Revenue Growth (YOY): 6.20%

Valuation Metrics

Enterprise Value: $1.17B
Trailing P/E: 72.46
Forward P/E: 6.44

Shares Statistics

Shares Outstanding: 39.86M
Shares Float: 36.19M
% Insiders: 1.74%
% Institutions: 113.26%
Short % Float: 26.43%

Stock Price History

1 Year Price History

3 Years Price History

10 Years Price History

Financial Charts

Revenue, Net Income & Operating Cash Flow (Yearly)

Revenue, Net Income & Operating Cash Flow (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$726.41M
Cost of Goods Sold
adjust
$-149.75M
Gross Profit
subtotal
$576.66M
SG&A
adjust
$-142.14M
R&D
adjust
$-117.31M
Other Operating Expense
adjust
$-283.90M
Operating Income
subtotal
$33.30M
Other / Non-Operating Items
adjust
$-26.27M
Net Income
subtotal
$7.03M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about PCRX.US!